CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

| More on:
A man looking at his laptop and thinking.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are edging higher on Tuesday morning.

At the time of writing, the biotechnology company's shares are up 0.5% to $271.68.

This follows the release of its half year results before the market open.

CSL shares edge higher on results day

Investors have been buying the company's shares this morning despite its results falling short of expectations for the six months ended 31 December.

CSL delivered a 5% increase in constant currency revenue to US$8.48 billion, a 7% increase in net profit after tax in constant currency to US$2.04 billion, and a 5% lift in NPATA in constant currency to US$2.11 billion.

The latter was a 4.1% short of the consensus estimate for the period.

Nevertheless, management has reaffirmed its full year guidance for FY 2025 and is forecasting revenue growth of 5% to 7% in constant currency.

And with further margin expansion expected in the second half, it has reiterated its guidance for NPATA of approximately US$3.2 billion to US$3.3 billion in constant currency. This represents growth of approximately 10% to 13% year on year.

And pleasingly, the company believes this double-digit earnings growth can continue over the medium term. It said:

The fundamentals of CSL's underlying business units are robust and CSL is in a strong position to deliver annualised double-digit earnings growth over the medium term. CSL's therapies continue to be valued by patients and healthcare systems around the world, as demonstrated by the continued growth of our core Ig franchise and the solid uptake of new product launches by CSL Vifor.

Broker reaction

Goldman Sachs has been running the rule over the result. While its analysts were disappointed with CSL's headline result, they were pleased with a stronger than expected performance from the key CSL Behring. They explain:

Mixed result with headline misses to group Revenue/ Gross Profit and NPATA (-0.7%/-2.2%/-4.1% vs cons) primarily driven by weakness in Seqirus, higher group SG&A costs and FX. Importantly, CSL's Behring Gross Profit segment was +1% ahead of consensus driven by a strong recovery in GM% (170 bps CC vs 1H24).

Given weakness in specialty sales, we believe the GM% accretion was primarily driven by solid progress on cost per litre reductions including optimizing donor fees, collection center efficiencies and fixed costs leverage on the fractionation side. Kcentra volume reduction was previously flagged by CSL with specialty sales in 1H25 weaker vs consensus by -10.4%.

It then concludes:

The weakness in Seqirus appears primarily driven by industry pressures with Sanofi and GSK reporting double digit revenue declines over the comparable period. However, compared to past periods, it appears market share gains have not been a key driver for CSL Seqirus this half. CSL Vifor was ahead of consensus expectations (+4.5% Gross Profit) with growth in iron sales and strong new product launches (TAVNEOS and FILSPARI). FY25 Constant Currency guidance was reiterated with FX headwind increased to $90m (vs $50m). Maintain Buy.

Goldman currently has a buy rating and $325.40 price target on CSL's shares.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

a group of people sit around a computer in an office environment.
Earnings Results

Guess which ASX 200 tech stock is rocketing 12% on record results

Another half, another record result from this high-quality company.

Read more »

A young man sitting at an outside table uses a card to pay for his online shopping.
Consumer Staples & Discretionary Shares

Why is the Kogan share price crashing 12%?

Profits are down at this ecommerce company during the second half.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Resources Shares

Guess which ASX 200 mining stock is sinking 7% following its quarterly update

Let's see how this miner performed during the third quarter.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

Up 50% in a year, are Xero shares a buy after Thursday's earnings results?

ASX investors reacted positively to Xero’s full-year earnings results on Thursday. Now what?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Earnings Results

Xero share price higher despite FY25 earnings miss

The cloud accounting platform provider reported strong top line growth but its earnings fell short of expectations.

Read more »

A man looking at his laptop and thinking.
Earnings Results

Why did the Aristocrat share price just plunge 13%?

Investors are smashing the Aristocrat share price today. But why?

Read more »

A woman wearing yellow smiles and drinks coffee while on laptop.
Earnings Results

CBA share price edges higher on $2.6b quarterly profit

Let's see how Australia's largest bank performed during the quarter.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Technology Shares

Life360 share price rockets 14% on record Q1 result

This market darling's rapid growth has continued so far in 2025.

Read more »